>
Switch to:

Cullinan Oncology Cash-to-Debt

: No Debt (As of Dec. 2019)
View and export this data going back to 2021. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cullinan Oncology's cash to debt ratio for the quarter that ended in Dec. 2019 was No Debt.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cullinan Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2019.

The historical rank and industry rank for Cullinan Oncology's Cash-to-Debt or its related term are showing as below:


Cullinan Oncology Cash-to-Debt Historical Data

The historical data trend for Cullinan Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Oncology Annual Data
Trend Dec18 Dec19 Dec20
Cash-to-Debt
No Debt No Debt No Debt

Cullinan Oncology Semi-Annual Data
Dec18 Dec19 Dec20
Cash-to-Debt No Debt No Debt No Debt

Competitive Comparison

For the Biotechnology subindustry, Cullinan Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cullinan Oncology Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cullinan Oncology's Cash-to-Debt falls into.



Cullinan Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cullinan Oncology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cullinan Oncology had no debt.

Cullinan Oncology's Cash to Debt Ratio for the quarter that ended in Dec. 2019 is calculated as:

Cullinan Oncology had no debt.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cullinan Oncology  (NAS:CGEM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Cullinan Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cullinan Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Oncology Business Description

Cullinan Oncology logo
Industry
Healthcare » Biotechnology NAICS : 541713 SIC : 2834
Comparable Companies
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Cullinan Oncology Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)